Skip to NavigationSkip to content

Pharmafile - Manufacturing and Production News

Top scientists from some of the UK’s foremost nuclear medicine associations have written a letter to recently-anointed Prime Minister Boris Johnson...
MSD's Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer; Cigarette smoke causes superbug to become more drug resistant...
MSD has announced a $650 million expansion of its existing facilities in North Carolina – a move which is bring more than 400 new jobs to the US...
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic indication...
Antibiotic resistant superbugs are spreading in hospitals in Europe, according to a study published in Nature Microbiology.
MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when...
Three pharmaceutical companies have agreed to pay $70 million to the state of California for keeping drug prices artificially high.
Pfizer’s off-patent drug unit Upjohn is combining with Mylan to create a new global pharmaceutical company focused on the low-price drug market.
FDA approves nine generic versions of Pfizer's Lyrica, NICE to review decision-making process, and Biohaven's amyotrophic lateral sclerosis drug...
Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio, showing that the therapy met its primary...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches